Literature DB >> 7682535

Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism.

P Vandenberghe1, J Verwilghen, F Van Vaeck, J L Ceuppens.   

Abstract

The CD5 and CD28 molecules on T lymphocytes can each exert an accessory role in T-cell activation. Ligands for CD5 and CD28 have been identified as CD72 and B7/BB1 respectively. The function of, and the signal transduction pathways coupled to CD28 have been the subject of extensive studies. In contrast, it is still debated whether CD5 functions as a receptor which directly transduces an independent signal to the T cell. In this paper, it is reported that culture of purified T cells in the presence of either immobilized anti-CD5 monoclonal antibody (mAb) (OKT1, Leu-1 or 10.2) or cross-linked anti-CD28 (9.3) mAb (but not of anti-LFA-1 alpha, anti-LFA-1 beta, or anti-CD7) induces expression of CD69, an early activation marker, in the absence of other activating stimuli. CD69 expression was consistently detectable after 3-24 hr on 20-50% of T cells, within both the CD4 and CD8 subsets. CD45RO- CD45RA+ naive T cells were more responsive than CD45RO+ CD45RA- memory T cells. In the presence of recombinant (r) interleukin-2 (IL-2), anti-CD5- or anti-CD28- induced CD69 expression was further up-regulated, more sustained and, as previously shown, succeeded by IL-2 responsiveness. Simultaneous cross-linking of both CD5 and CD28 enhanced CD69 expression above the levels obtained with optimal amounts of both ligands separately. In the presence of a submitogenic dose of the protein kinase C (PKC) activating agent phorbol 12-myristate 13-acetate (PMA), co-stimulation with anti-CD5 or anti-CD28 increased CD69 expression above that induced by PMA alone. Cross-linking of CD5 or CD28 induces an early rise of cytoplasmic free calcium concentration ([Ca2+)]i) and both this rise and CD69 expression were inhibited by chelation of extracellular Ca2+ with ethyleneglycol-bis-(2-aminoethyl)-tetraacetate (EGTA). Pretreatment of the cells with the tyrosine kinase inhibitor herbimycin A also blocked CD69 expression. The data thus antigen-independent fashion. Moreover it is demonstrated that influx of Ca2+ and tyrosine kinase activity are involved in the signal transduction pathways of both receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682535      PMCID: PMC1421815     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes.

Authors:  L A Turka; J A Ledbetter; K Lee; C H June; C B Thompson
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

2.  MLR3 molecule is an activation antigen shared by human B, T lymphocytes and T cell precursors.

Authors:  A Risso; M E Cosulich; A Rubartelli; M R Mazza; A Bargellesi
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

3.  Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C.

Authors:  R Testi; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

4.  Expression and function of AIM, an activation inducer molecule of human lymphocytes, is dependent on the activation of protein kinase C.

Authors:  M Cebrián; J M Redondo; A López-Rivas; G Rodríguez-Tarduchy; M O De Landázuri; F Sánchez-Madrid
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

5.  Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds.

Authors:  Y Uehara; H Fukazawa; Y Murakami; S Mizuno
Journal:  Biochem Biophys Res Commun       Date:  1989-09-15       Impact factor: 3.575

6.  Constitutive expression of a phosphorylated activation antigen (Leu 23) by CD3bright human thymocytes.

Authors:  R Testi; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

7.  Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.

Authors:  J A Ledbetter; P J Martin; C E Spooner; D Wofsy; T T Tsu; P G Beatty; P Gladstone
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens.

Authors:  M L Baroja; K Lorre; F Van Vaeck; J L Ceuppens
Journal:  Cell Immunol       Date:  1989-04-15       Impact factor: 4.868

9.  Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes.

Authors:  M Cebrián; E Yagüe; M Rincón; M López-Botet; M O de Landázuri; F Sánchez-Madrid
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

10.  Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen).

Authors:  T Hara; S M Fu; J A Hansen
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  14 in total

1.  Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.

Authors:  Rebecca Blackstock
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

2.  Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway.

Authors:  M T Anderson; F J Staal; C Gitler; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

3.  Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation.

Authors:  P E Simms; T M Ellis
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

4.  A whole-blood assay for qualitative and semiquantitative measurements of CD69 surface expression on CD4 and CD8 T lymphocytes using flow cytometry.

Authors:  L C Lim; M N Fiordalisi; J L Mantell; J L Schmitz; J D Folds
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

5.  CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor.

Authors:  F Borrego; M J Robertson; J Ritz; J Peña; R Solana
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

6.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

7.  Characterization of porcine CD5 and CD5+ B cells.

Authors:  G D Appleyard; B N Wilkie
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

8.  CD5 (OKT1) augments CD3-mediated intracellular signaling events in human T lymphocytes.

Authors:  S M Berney; T Schaan; R E Wolf; D L Kimpel; H van der Heyde; T P Atkinson
Journal:  Inflammation       Date:  2001-08       Impact factor: 4.092

9.  Flow cytometric characterisation of the "false naive" (CD45RA+, CD45RO-, CD29 bright+) peripheral blood T-lymphocytes in health and in rheumatoid arthritis.

Authors:  M Neidhart; F Pataki; J Schönbächler; P Brühlmann
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

10.  Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

Authors:  Jang Hwan Cho; James J Collins; Wilson W Wong
Journal:  Cell       Date:  2018-04-26       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.